BioAge Labs, Inc.

More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102 - TradingView

HitGen Partner BioAge Labs Doses First Participant In Phase 2 Trial Of BGE-102 TradingView

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction - PR Newswire

HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction PR Newswire

Price to book forward of BioAge Labs, Inc. – DUS:Y7G - TradingView

Price to book forward of BioAge Labs, Inc. – DUS:Y7G TradingView

How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure - Sahm

How Broad Russell Growth Index Inclusion Could Shape BioAge Labs (BIOA) Investor Exposure Sahm